Brief: TOT Biopharm Says Predefined Primary Endpoint Of Randomized Phase III Clinical Trial Of Tab008 Recently Met
21/04/2020 12:26
April 21 (Reuters) - TOT BIOPHARM International Co Ltd
1875.HK :
* PREDEFINED PRIMARY ENDPOINT IN RELATION TO RANDOMIZED
PHASE III
CLINICAL TRIAL OF TAB008 RECENTLY MET
Source text for Eikon: urn:newsml:reuters.com:*:nHKS1mShyB
Further company coverage: 1875.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29